TY - JOUR
T1 - CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias
AU - Chakhachiro, Zaher I.
AU - Zuo, Zhuang
AU - Aladily, Tariq N.
AU - Kantarjian, Hagop M.
AU - Cortes, Jorge E.
AU - Alayed, Khaled
AU - Nguyen, Martin H.
AU - Medeiros, L. Jeffrey
AU - Bueso-Ramos, Carlos
PY - 2013/9
Y1 - 2013/9
N2 - Objectives: To assess CD105 (endoglin) expression in 119 acute myeloid leukemia (AML) and 13 control cases using immunohistochemistry. Methods: CD105 expression was assessed retrospectively by using immunohistochemistry in bone marrow specimens. Results: CD105 was strongly and diffusely positive in all 9 (100%) AMLs with t(15;17)(q24.1;q21.2), 2 (100%) AMLs with t(8;21)(q22;q22), 1 (100%) AML with t(6;9)(p23;q34), 7 (28%) of 25 AMLs with myelodysplasia-related changes, 1 (33%) of 3 therapy-related AMLs, 3 (16%) of 19 AMLs unclassifiable, 1 (14%) of 7 AMLs with inv(16)(p13.1q22), and 5 (11%) of 45 AMLs not otherwise specified. Uninvolved bone marrow in these cases showed no CD105 expression by erythroid precursors, megakaryocytes, or endothelial or stromal cells. Two of 13 control bone marrow specimens showed partial CD105 positivity in myeloid cells. In 21 strongly CD105+ AML cases tested for the IDH2 mutation, 9 (42%) were mutated (P = .004). Conclusions: These data suggest that CD105 could be a therapeutic target in a subset of patients with AML.
AB - Objectives: To assess CD105 (endoglin) expression in 119 acute myeloid leukemia (AML) and 13 control cases using immunohistochemistry. Methods: CD105 expression was assessed retrospectively by using immunohistochemistry in bone marrow specimens. Results: CD105 was strongly and diffusely positive in all 9 (100%) AMLs with t(15;17)(q24.1;q21.2), 2 (100%) AMLs with t(8;21)(q22;q22), 1 (100%) AML with t(6;9)(p23;q34), 7 (28%) of 25 AMLs with myelodysplasia-related changes, 1 (33%) of 3 therapy-related AMLs, 3 (16%) of 19 AMLs unclassifiable, 1 (14%) of 7 AMLs with inv(16)(p13.1q22), and 5 (11%) of 45 AMLs not otherwise specified. Uninvolved bone marrow in these cases showed no CD105 expression by erythroid precursors, megakaryocytes, or endothelial or stromal cells. Two of 13 control bone marrow specimens showed partial CD105 positivity in myeloid cells. In 21 strongly CD105+ AML cases tested for the IDH2 mutation, 9 (42%) were mutated (P = .004). Conclusions: These data suggest that CD105 could be a therapeutic target in a subset of patients with AML.
KW - Acute myeloid leukemia
KW - CD105
KW - Endoglin
KW - IDH2 mutation
KW - Immunohistochemistry
UR - http://www.scopus.com/inward/record.url?scp=84882795736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882795736&partnerID=8YFLogxK
U2 - 10.1309/AJCPG8XH7ZONAKXK
DO - 10.1309/AJCPG8XH7ZONAKXK
M3 - Article
C2 - 23955456
AN - SCOPUS:84882795736
SN - 0002-9173
VL - 140
SP - 370
EP - 378
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 3
ER -